García-Pedro EE, Jiménez-Mejía DC, Tafoya-Ramírez F, Arango-Cruz C, Orellana-Centeno JE, Pérez-Cruz VH

Language: Spanish
References: 15
Page: 309-315
PDF size: 396.17 Kb.

ABSTRACT

Introduction: Primary uterine salpinge cancer is a rare malignant neoplasm of the female genital tract, corresponding to 0.1-1.8% of gynecologic malignancies. It occurs mainly in menopausal or post-menopausal patients, with a higher incidence between 55-65 years of age. Pacient and methods: We present the case of a 63-year-old patient with the diagnosis of primary salpinge carcinoma, since the patient came to the consultation for abdominal pain, increased abdominal perimeter, ascites, and weight loss of approximately 5 kilos, from the beginning of her Symptoms reported by CT Ascites, Carcinomatosis as well as probable pelvic tumor dependent on the right ovary, he was admitted to the exploratory laparotomy with findings of a tumor dependent on the right ovary, peritoneal carcinomatosis and abundant ascites fluid, optimal cytoreduction was performed and the samples were sent to the service of Pathology of our unit, reaching the definitive diagnosis by histopathology and immunohistochemistry of high-grade carcinoma, of the right salpinge, affecting the muscle layer surpassing it. Conclusion: It is a rare pathology with survival varying in some studies around 20- 60%, depending on the FIGO stage. Treatment is based on surgery and postoperative chemotherapy.

REFERENCES

1. Medeiros F, Muto MG, Lee Y, Elvin JA, CallahanMJ, Feltmate C, et al. La fimbria tubáricaes un sitio preferido para el adenovarcinomatemprano en mujeres con síndromede cáncer de ovario familiar. J SurgPathol. 2006; 30(2): 230–6.

2. Puig F, Lapresta M, Lanzan A, Crespo R.Carcinoma de trompa de Falopio: hallazgoincidental durante cirugía por enfermedadpélvica inflamatoria aguda-informe decaso. Eur J Gynaecol Oncol. 2006; 27: 526–7.

3. Singhal P, Odunsin K, Rodabangh K, DriscollD, Lele S. Carcinoma de trompa de Falopioprimario: un estudio clinicopatológicoretrospectivo. Eur J Gynaecol Oncol. 2006;27(1): 16–8.

4. Pectasides D, Pectasides E, EconomopoulosT. Fallopian tube carcinoma: a review.Oncologist [Internet]. 2006; 11(8): 902–12.

5. Rosenbla KA, Weiss NS, Schwartz SM. Incidenceof malignant fallopian tube tumors.Gynecol Oncol. 1989; 35: 236–9.

6. Wolfson AH, Tralins KS, Greven KM, Kin RY,Corn BW, Kiettel MR, et al. Adenocarcinomade trompa de Falopio: resultados de un análisisretrospectivo multiinstitucional de 72 pacientes.Int J Radiat Oncol Biol Phys1998. 40: 71–6.

7. Riska A, Leminen A, Pukkala E. Determinantessociodemográficos de la incidencia delcarcinoma primario de trompas de Falopio,Finlandia 1953-1957. Int J Cáncer. 2003;104(5): 902–12.

8. Baekelandt M, Kockx M, Wesling F, Gerris J.Primary adenocarcinoma of the fallopiantube. Review of the literature. Int J GynecolCancer [Internet]. 1993; 3(2): 65–71.

9. Lin C-K, Chang C-C, Pan S-H, Yu M-H. Primaryfallopian tube cancer may mimic endometrialmalignancy. Taiwan J Obstet Gynecol[Internet]. 2008; 47(2): 218–9.

10. Ajithkumar TV, Minimole AL, John MM,Ashokkumar OS. Primary fallopian tube carcinoma.Obstet Gynecol Surv [Internet].2005; 60(4): 247–52.

11. Eddy GL, Copeland LJ, Gershenson DM.Second-look laparotomy in fallopian tubecarcinoma. Gynecol Oncol [Internet]. 1984;19(2):182–6.

12. Monge AH, Pineda RP, Hernandez M, JuárezEG, García JC. Adenocarcinoma Invasorprimario de trompa de Falopio concomitantecon enfermedad pélvica inflamatoria aguda.Comunicación de un cado y revisión de la literatura.Ginecol Obstet Mex. 2008; 76:118–24.

13. Riska A, Alfthan H, Finne P, Jalkanen J,Sorvari T, Stenman UH. Preoperative serumhCGbeta as a prognostic marker in primaryfallopian tube carcinoma Tumour. Biol. TumourBiol. 2006; 27: 43–9.

14. Briceño W, Spagnuolo L, Palacios P. Adenocarcinomade trompa de Falopio. Rev VenezOncol. 1991; 3(1): 35–9.

15. Wethington L. Improved survival for fallopiantube cancer; A comparison of clinical characteristicsand outcome for primary fallopiantube and ovarian cancer. Ame. Ca. Soc2008; 113(12): 3298-306.